Search IPOs
SPML · BSE · Pharmaceuticals
Speciality Medicines IPO listed on 30 Mar 2026 on BSE at ₹124.00, a gain of 0.00% over the issue price of ₹124.00. The IPO was subscribed 2.27x overall.
Speciality Medicines IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 20 Mar 2026 |
| IPO Close Date | 24 Mar 2026 |
| Basis of Allotment | 25 Mar 2026 |
| Initiation of Refunds | 27 Mar 2026 |
| Credit of Shares to Demat | 27 Mar 2026 |
| Listing Date | 30 Mar 2026 |
Listing day gain
+0%
Listed at ₹124 (issue ₹124)
Issue
₹124
Listing
₹124
Current
₹125.9
+1.53% vs issue
Day range
₹124 – ₹129.5
Issue Size
2,350,000 shares
(aggregating up to ₹29.00 Cr)
Issue Price
₹117 – ₹124
Face Value
₹10/share
Market Lot
1,000 shares
Retail Min Investment
₹248,000
Listing At
BSE
Sale Type
fresh issue
Fresh Issue
2,200,000 shares
(aggregating up to ₹27 Cr)
Offer for Sale
[.]
Reserved for Market Maker
150,000 shares
(aggregating up to ₹2.00 Cr)
Issue Type
book building
Open Date
20 Mar
Close Date
24 Mar
Allotment
25 Mar
Listing
30 Mar
Last updated: 6 months ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 30 Mar 2026 Latest | ₹124 | ₹0 | ₹124 | ₹0 |
0%
|
2:40 PM |
| 29 Mar 2026 | ₹124 | ₹0 | ₹124 | ₹0 |
0%
|
11:22 AM |
Showing the 2 most recent GMP entries.
View full GMP historyLatest snapshot: 24 Mar 2026
| Category | Subscribed (x) | No. of Applications |
|---|---|---|
| QIB | 96.24x | - |
| NII | 1.88x | - |
| bNII (bids above ₹10L) | 2.5x | - |
| sNII (bids below ₹10L) | 0.64x | - |
| Retail Investors | 0.85x | - |
| Total | 2.27x | - |
Showing the latest subscription snapshot.
View full subscription historyParth B Goyani and Goyani Sumit Babubhai are the promoters of the company.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹248,000 |
| Retail (Max) | 2 | 2,000 | ₹248,000 |
| S-HNI (Min) | 3 | 3,000 | ₹372,000 |
| S-HNI (Max) | 8 | 8,000 | ₹992,000 |
| B-HNI (Min) | 9 | 9,000 | ₹1,116,000 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 150,000 (6.38%) |
| QIB Shares Offered | 21,000 (0.89%) |
| NII (HNI) Shares Offered | 1,089,000 (46.34%) |
|
•
bNII > ₹10L
|
726,000 (30.89%) |
|
•
sNII < ₹10L
|
363,000 (15.45%) |
| Retail Shares Offered | 1,090,000 (46.38%) |
| Total Shares Offered | 2,350,000 (99.99%) |
Speciality Medicines Limited is a pharmaceutical company that focuses on selling and distributing high-end medicines. They deal with specialized treatments like oral and injectable drugs for complex chronic diseases. They don't just sell in India; they have a network covering over 35 countries, working with international partners to provide finished medical products.
Strengths:
The company has a very strong global footprint for a young firm, with products already registered or being registered in countries like Jordan, Ethiopia, Uganda, and Peru. One of their biggest strengths is their "Asset Light" model—they focus on marketing and distribution rather than heavy factory costs. They have shown impressive financial growth, with their Profit After Tax (PAT) jumping from ₹1.69 Cr in FY23 to ₹4.55 Cr in FY24. Their Return on Equity (ROE) is remarkably high at over 40%, showing they are very efficient at using shareholders' money to generate profit.
Growth:
The company is planning to use the IPO money to shift to the next level by setting up their own Research and Development (R&D) Center (budgeted at ₹13.31 Cr). This will help them create their own unique medical formulations. They are also investing heavily in international product registrations, which will open doors to more foreign markets. By expanding their distribution network across more Indian states and increasing their global reach, they are moving from being a simple distributor to a full-scale pharmaceutical player with its own research capabilities.
Standalone · ₹ in Crores
| Particulars | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Total Revenue | 40.45 | 23.26 | 27.66 |
| Profit After Tax (PAT) | 1.48 | 1.69 | 4.55 |
| EBITDA | - | - | - |
| Total Assets | 5.78 | 13.26 | 23.43 |
| Net Worth | 1.93 | 5.78 | 16.61 |
| Reserves & Surplus | 1.72 | 2.05 | 11.5 |
| Total Borrowing | 1.18 | 3.64 | 2.86 |
Revenue & Profit Trend
The basis of allotment for Speciality Medicines IPO was finalised on 25 Mar 2026. You can check your allotment status using your PAN number or application number on the Skyline Financial Services Pvt.Ltd. portal or BSE.
The Speciality Medicines IPO is expected to open in Mar 2026, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Speciality Medicines IPO is ₹117.00 - ₹124.00 per share.
As per market sources, Speciality Medicines IPO GMP is currently ₹0.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Speciality Medicines IPO stands at 2.27x overall.
The listing date for Speciality Medicines IPO is 30 Mar 2026.
No comments yet. Be the first to comment!
